Occupational HIV Postexposure Prophylaxis With Darunavir/r.
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Efavirenz; Lopinavir/ritonavir; Nucleotide reverse transcriptase inhibitors; Zidovudine
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Acronyms PEPDar
- Sponsors Janssen-Cilag
- 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
- 01 Sep 2013 Primary endpoint 'Treatment-discontinuation' has been met.
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History